Drug Profile
Encelimab - AnaptysBio/GSK
Alternative Names: GSK-4074386; TSR 033Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AnaptysBio
- Developer AnaptysBio; GSK
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 13 Feb 2023 Tesaro completes phase-I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France and US (Parenteral) (NCT03250832)
- 03 Feb 2023 Encelimab is still in phase-I trials in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France and USA (Parenteral) (NCT03250832) (GlaxoSmithKline pipeline, February 2023)
- 03 Feb 2023 Encelimab is still in phase-I trials in Solid-tumours(Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France and USA (Parenteral) (NCT03250832) (GlaxoSmithKline pipeline, February 2023)